62 results
6-K
EX-99.1
SLN
Silence Therapeutics Plc
13 Mar 24
Current report (foreign)
7:10am
of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company’s cash runway and forecast
6-K
EX-99.1
SLN
Silence Therapeutics Plc
23 Feb 24
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca
8:12am
Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
6-K
EX-99.1
SLN
Silence Therapeutics Plc
6 Feb 24
Securities Purchase Agreement
12:00am
the Company, without re-examination or review of the merits of the cause of action in respect of which the original judgment was given or re-litigation … materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall
6-K
EX-99.2
SLN
Silence Therapeutics Plc
6 Feb 24
Securities Purchase Agreement
12:00am
or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees … in respect of such claim or litigation.
6.4. Contribution. If for any reason the indemnification provided for in the preceding Sections 6.1 and 6.2
6-K
EX-99.1
n4tkxq2t
1 Dec 23
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
7:00am
6-K
EX-99.1
fb6r6j2gwiqj4
14 Nov 23
Current report (foreign)
12:00am
6-K
EX-99.1
dx1hst2mkr
1 Nov 23
Current report (foreign)
7:00am
6-K/A
EX-99.1
3c34j 3sa
29 Aug 23
Current report (foreign) (amended)
4:01pm
6-K
EX-99.1
x4s zla131f4
16 Aug 23
Current report (foreign)
7:00am
6-K
EX-99.1
hkksjx00prz m6i
11 Jul 23
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
7:00am
6-K
EX-99.1
qt8ovvwcv6jy
16 May 23
Current report (foreign)
4:01pm
6-K
EX-99.1
s46vs1h13mg
4 May 23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
7:41am
6-K
EX-99.1
jy64vl4h 1ilsdvz11l
1 May 23
Current report (foreign)
7:31am
6-K
EX-99.1
2h7tuyqcc01 mj3p
10 Nov 22
Current report (foreign)
8:30am
6-K
EX-99.1
wnnm3kfvpyaf4uzf7
7 Nov 22
Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period
8:30am
6-K
EX-99.1
3u42j23wf8kvmx9g
29 Sep 22
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
8:00am
6-K
EX-1.1
zz0sbxxftxlvz iuwor
16 Aug 22
Current report (foreign)
4:43pm
424B5
625syvlvh7a rfm64g5
12 Aug 22
Prospectus supplement for primary offering
1:32pm
6-K
EX-99.1
d0si5wdf8w7nnhx4d1y
12 Aug 22
Silence Therapeutics Announces Pricing of Underwritten Offering
6:07am